Biosimilar Groups Seek ‘Structural’ Changes in U.S. Market

Drug Industry Daily
A A
Biosimilar groups are pressing federal agencies including the FDA to make “structural” changes to the biosimilar marketplace, claiming that the U.S. is falling far behind Europe on cheaper treatments.

To View This Article:

Login

Subscribe To Drug Industry Daily